The MHRA’s Interim Executive Director of Science and Research writes in The British Medical Journal on the approval of the UK’s first new UTI antibiotic in nearly 30 years, and the wider challenge of tackling antibiotic resistance.
Similar Posts
If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy
Guidance: A guide to defective medicinal products
Reporting, investigating and recalling suspected defective medicinal products to the Defective Medicines Report Centre (DMRC).
Guidance: MORE Registrations – user reference guide
A step-by-step guide on using the MORE Platform for Registrations for Submissions of device related incidents.
Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film, EL(25)A/47
Zambon SpA is recalling an affected batch as a precautionary measure due to out of specification results for unknown impurities during ongoing stability testing.
MHRA approves lenacapavir for the prevention of sexually transmitted HIV-1 infection
As with any medicine, the MHRA will keep the safety and effectiveness of lenacapavir under close review.
Decision: Advertising Investigations: May 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.